Methods for predicting and treating myocardial damage

Abstract

A method for predicting myocardial damage in a subject having or at risk of cardiac disease includes determining a level of apolipoprotein AI (ApoAI) and a level of Coenzyme Q 10 (CoQ 10 ) in the subject and comparing the determined levels of ApoAI and CoQ 10 to control levels.

1 . A method for predicting myocardial damage in a subject having or at risk of cardiac disease, the method comprising:
 determining a level of apolipoprotein AI (ApoAI) in the subject;   determining a level of Coenzyme Q 10  (CoQ 10 ) in the subject;   comparing the determined levels of ApoA1 and CoQ 10  to control levels, wherein a decreased level of ApoAI and a decreased level of CoQ 10  compared to control levels are indicative of the subject having an increased risk of greater myocardial damage following a myocardial infarction.   
     
     
         2 . The method of  claim 1 , further comprising the step of obtaining one or more bodily samples from the subject, the one or more bodily samples including CoQ 10  and ApoAI. 
     
     
         3 . The method of  claim 2 , the one or more bodily samples comprising plasma. 
     
     
         4 . The method of  claim 1 , wherein the level of ApoAI in the subject is determined using an ELISA assay. 
     
     
         5 . The method of  claim 1 , wherein the level of CoQ 10  in the subject is determined using high-performance liquid chromatography. 
     
     
         6 . The method of  claim 1 , wherein the myocardial damage comprises a ratio of an area of ischemic myocardial tissue to total area of myocardial tissue. 
     
     
         7 . The method of  claim 1 , the control levels include normal levels of ApoA1 and CoQ10 in a population of apparently healthy subjects. 
     
     
         8 . The method of  claim 1 , wherein the cardiac disease is selected from the group consisting of myocardial infarction, coronary artery disease, angina, atherosclerosis, aneurysm, congestive heart failure, left ventricular dysfunction, cerebrovascular disease, and cerebrovascular accident. 
     
     
         9 . A method of determining increased risk of greater myocardial damage in a subject having or at risk of cardiac disease, the method comprising:
 determining a level of apolipoprotein AI (ApoAI) in the subject;   determining a level of Coenzyme Q 10  (CoQ 10 ) in the subject;   comparing the determined levels of ApoA1 and CoQ 10  to control levels, wherein a decreased level of ApoAI and a decreased level of CoQ 10  compared to control levels are indicative of the subject having an increased risk of greater myocardial damage following a myocardial infarction.   
     
     
         10 . The method of  claim 9 , further comprising the step of obtaining one or more bodily samples from the subject, the one or more bodily samples including CoQ 10  and ApoAI. 
     
     
         11 . The method of  claim 10 , the one or more bodily samples comprising plasma. 
     
     
         12 . The method of  claim 9 , wherein the level of ApoAI in the subject is determined using an ELISA assay. 
     
     
         13 . The method of  claim 9 , wherein the level of CoQ 10  in the subject is determined using high-performance liquid chromatography. 
     
     
         14 . The method of  claim 9 , wherein the myocardial damage comprises a ratio of an area of ischemic myocardial tissue to total area of myocardial tissue. 
     
     
         15 . The method of  claim 9 , the control levels include normal levels of ApoA1 and CoQ10 in a population of apparently healthy subjects. 
     
     
         16 . The method of  claim 9 , wherein the cardiac disease is selected from the group consisting of myocardial infarction, coronary artery disease, angina, atherosclerosis, aneurysm, congestive heart failure, left ventricular dysfunction, cerebrovascular disease, and cerebrovascular accident. 
     
     
         17 . A method of determining increased risk of greater myocardial damage in a subject having or at risk of cardiac disease, the method comprising:
 determining a level of HDL in the subject;   determining a level of Coenzyme Q 10  (CoQ 10 ) in the subject;   comparing the determined levels of ApoA1 and CoQ 10  to control levels, wherein a decreased level of ApoAI and a decreased level of CoQ 10  compared to control levels are indicative of the subject having an increased risk of greater myocardial damage following a myocardial infarction.   
     
     
         18 . The method of  claim 17 , further comprising the step of obtaining one or more bodily samples from the subject, the one or more bodily samples including CoQ 10  and HDL. 
     
     
         19 . The method of  claim 18 , the one or more bodily samples comprising plasma. 
     
     
         20 . The method of  claim 17 , wherein the level of HDL in the subject is determined using a fluorometric assay. 
     
     
         21 . The method of  claim 17 , wherein the level of CoQ 10  in the subject is determined using high-performance liquid chromatography. 
     
     
         22 . The method of  claim 17 , wherein the myocardial damage comprises a ratio of an area of ischemic myocardial tissue to total area of myocardial tissue. 
     
     
         23 . The method of  claim 17 , the control levels include normal levels of HDL and CoQ10 in a population of apparently healthy subjects. 
     
     
         24 . The method of  claim 17 , wherein the cardiac disease is selected from the group consisting of myocardial infarction, coronary artery disease, angina, atherosclerosis, aneurysm, congestive heart failure, left ventricular dysfunction, cerebrovascular disease, and cerebrovascular accident. 
     
     
         25 - 33 . (canceled)